Clinical Trial Update: Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating chimeric monoclonal antibodies against Shiga toxins 1 and 2 has completed. The study, sponsored by Thallion Pharmaceuticals, i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Shiga Toxin-producing Bacterial Infection

Drugs mentioned

• Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2

Snippet

Sponsor: Thallion Pharmaceuticals | Conditions: Shiga Toxin Producing Bacterial Infection | Phase 2 | Status: COMPLETED